Insulin Drug Slows Type 1 Diabetes Progression

French manufacturer Sanofi produces Trizield, a drug designed to slow the progression of Type 1 diabetes in children starting from age one. The medication does not cure the disease but works by suppressing the autoimmune response to preserve insulin-producing pancreatic cells. This intervention aims to delay the onset of stage three diabetes, which requires insulin injections. The treatment is specifically targeted at patients in the early stages of the disease before symptoms become severe. Researchers at a French laboratory have developed a drug that slows the progression of Type 1 diabetes. The treatment is being targeted toward a demographic, specifically focusing on the 128 million people in the United States with diabetes or pre-diabetes who do not currently use intensive insulin. In the US, only 10 million of the 138 million people living with diabetes or pre-diabetes are classified as intensive insulin users. The research aims to address the broader population rather than just those already on intensive regimens. The study's findings suggest potential for long-term management of the condition. Researchers are evaluating the impact on a target audience of approximately 128 million people. January AI has developed a virtual sensor for continuous monitoring that avoids invasive arm insertions. The technology has shown success in helping pre-diabetic individuals evade the onset of diabetes.